Bad news for Innate Pharma as BMS-backed drug stumbles
Bristol-Myers Squibb | November 23, 2017
French biotech Innate Pharma says it can’t see a development path forward for its lead cancer drug lirilumab after another clinical trial miss. The Bristol-Myers Squibb-partnered checkpoint inhibitor, licensed in a $465m deal in 2011.